ATE352295T1 - Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten - Google Patents

Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten

Info

Publication number
ATE352295T1
ATE352295T1 AT02777571T AT02777571T ATE352295T1 AT E352295 T1 ATE352295 T1 AT E352295T1 AT 02777571 T AT02777571 T AT 02777571T AT 02777571 T AT02777571 T AT 02777571T AT E352295 T1 ATE352295 T1 AT E352295T1
Authority
AT
Austria
Prior art keywords
sub
mediated diseases
cell
quinazolines
treat
Prior art date
Application number
AT02777571T
Other languages
English (en)
Inventor
Nelly Corine Moore
Keith Oldham
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE352295T1 publication Critical patent/ATE352295T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02777571T 2001-11-23 2002-11-20 Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten ATE352295T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128109.6A GB0128109D0 (en) 2001-11-23 2001-11-23 Therapeutic use

Publications (1)

Publication Number Publication Date
ATE352295T1 true ATE352295T1 (de) 2007-02-15

Family

ID=9926330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777571T ATE352295T1 (de) 2001-11-23 2002-11-20 Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten

Country Status (7)

Country Link
US (1) US7157467B2 (de)
EP (1) EP1453492B1 (de)
AT (1) ATE352295T1 (de)
AU (1) AU2002339194A1 (de)
DE (1) DE60217904T2 (de)
GB (1) GB0128109D0 (de)
WO (1) WO2003045364A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2005536486A (ja) * 2002-07-09 2005-12-02 アストラゼネカ アクチボラグ 癌の処置に使用するためのキナゾリン誘導体
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
PL205557B1 (pl) * 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
RU2267489C2 (ru) * 2000-08-21 2006-01-10 Астразенека Аб Производные хиназолина, способ их получения и фармацевтическая композиция

Also Published As

Publication number Publication date
US20050014773A1 (en) 2005-01-20
US7157467B2 (en) 2007-01-02
EP1453492B1 (de) 2007-01-24
GB0128109D0 (en) 2002-01-16
DE60217904T2 (de) 2007-11-15
WO2003045364A2 (en) 2003-06-05
EP1453492A2 (de) 2004-09-08
DE60217904D1 (de) 2007-03-15
WO2003045364A3 (en) 2003-08-28
AU2002339194A1 (en) 2003-06-10
AU2002339194A8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
DE60204722D1 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
DE60329533D1 (de) Cyclische sulfamide zur inhibierung von gamma-sekretase
CY1107539T1 (el) Παραγωγα κουιναζολινης
GB0226931D0 (en) Chemical compounds
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
HK1067128A1 (en) Beta-carbolin derivatives as ptp-inhibitors
DE69935133D1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
HK1051691A1 (en) Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
ATE352295T1 (de) Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE59202618D1 (de) BIOTENSIDE ESTER MIT VITAMIN-D-VERBINDUNGEN; IHRE HERSTELLUNG UND AUFARBEITUNG ZU SPONTAN DISPERGIERBAREN kONZENTRATEN, SOWIE IHRE VERWENDUNG ZUR BEHANDLUNG VON TUMOREN.
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE69333962D1 (de) Modifizierte zellen auf der basis des betain-katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen
ATE380789T1 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE431399T1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
DE50207119D1 (de) 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60312840D1 (de) Verwendung von hydroxypyridon derivaten zur wundheilung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties